SEMHF (Siemens Healthineers AG) Cash And Cash Equivalents : $2,905 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Siemens Healthineers AG Cash And Cash Equivalents?

Siemens Healthineers AG's quarterly cash and cash equivalents increased from Jun. 2024 ($2,213.13 Mil) to Sep. 2024 ($2,977.80 Mil) but then stayed the same from Sep. 2024 ($2,977.80 Mil) to Dec. 2024 ($2,904.71 Mil).

Siemens Healthineers AG's annual cash and cash equivalents increased from Sep. 2022 ($1,421.78 Mil) to Sep. 2023 ($2,398.08 Mil) and increased from Sep. 2023 ($2,398.08 Mil) to Sep. 2024 ($2,977.80 Mil).

Siemens Healthineers AG Cash And Cash Equivalents Historical Data

The historical data trend for Siemens Healthineers AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Siemens Healthineers AG Cash And Cash Equivalents Chart

Siemens Healthineers AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Cash And Cash Equivalents

Get a 7-Day Free Trial

772.67

1,555.29

1,421.78

2,398.08

2,977.80

Siemens Healthineers AG Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,598.69	2,505.44	2,213.13	2,977.80	2,904.71

Siemens Healthineers AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Siemens Healthineers AG (OTCPK:SEMHF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Siemens Healthineers AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Siemens Healthineers AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Siemens Healthineers AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (OTCPK:SEMHF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

SMMNY:USA 1SHL:Italy SHLd:UK 0PMJ:UK SHL:Germany SHL:Bulgaria SHL:Austria

Address

Siemensstrasse 3, Forchheim, BY, DEU, 91301

Website

https://www.siemens-healthineers.com

Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2023) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (16% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (21%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. North America represents 41% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific including China the remainder.